The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.

@article{Hanania2012TheEA,
  title={The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.},
  author={Nicola Alexander Hanania and Gregory J. Feldman and Wolfgang Zachgo and Jae-Jeong Shim and Courtney C Crim and Lisa Sanford and Sally Lettis and Frank Barnhart and Brett K Haumann},
  journal={Chest},
  year={2012},
  volume={142 1},
  pages={119-127}
}
BACKGROUND Vilanterol (GW642444M) (VI) is a novel, inhaled, long-acting β(2) agonist with inherent 24-h activity under development as a once-daily combination therapy with an inhaled corticosteroid for COPD and asthma. This study assessed the dose response, efficacy, and safety of VI at doses of 3 to 50 μg in patients with moderate to severe COPD. METHODS Six hundred two patients (intent-to-treat) were randomized (double-blind) to VI 3, 6.25, 12.5, 25, or 50 μg or placebo once daily for 28… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 10 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA.

International journal of chronic obstructive pulmonary disease • 2016
View 14 Excerpts
Highly Influenced

Discovering the Relative Efficacy of Inhaled Medications for Chronic Obstructive Pulmonary Disease: Multiple Treatment Comparisons.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology • 2017

Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle

International journal of chronic obstructive pulmonary disease • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…